Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dopamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.68 |
| ▸ | DRD2 | P14416 | 2/20 | 0.68 |
| ▸ | DRD1 | P21728 | 2/20 | 0.68 |
| ▸ | DRD4 | P21917 | 2/20 | 0.68 |
| ▸ | DRD5 | P21918 | 2/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | DRD3 | P35462 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 2/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.68 |
| ▸ | APEX1 | P27695 | 2/20 | 0.68 |
| ▸ | THPO | P40225 | 2/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dopamine SCHEMBL20696071 | 1.00 | KDM4E (0.68) | KDM4EMAPTTDP1ALOX15ADRA2A | |
| Nonanoate SCHEMBL29220026 | 0.87 | MAPT (0.60) | KDM4EMAPTTDP1ALOX15ADRA2A | |
| Dopamine SCHEMBL30355306 | 0.86 | KDM4E (0.84) | KDM4EMAPTTDP1ALOX15ADRA2A | |
| Dopamine SCHEMBL28995038 | 0.86 | KDM4E (0.84) | KDM4EMAPTTDP1ALOX15ADRA2A | |
| Dopamine SCHEMBL246139 | 0.86 | KDM4E (0.66) | KDM4EMAPTTDP1ALOX15ADRA2A | |
| Dopamine SCHEMBL29082656 | 0.85 | KDM4E (0.79) | KDM4EMAPTTDP1ALOX15ADRA2A | |
| SCHEMBL18788836 | 0.84 | IGF1R (0.67) | KDM4EMAPTTDP1ALOX15MAPK1 | |
| Dopamine SCHEMBL5441164 | 0.84 | KDM4E (0.81) | KDM4EMAPTTDP1ALOX15ADRA2A | |
| 3,4-Dihydroxyphenylacetic Acid SCHEMBL8565392 | 0.83 | GAA (0.76) | KDM4EMAPTTDP1ALOX15ADRA2A | |
| Dopamine SCHEMBL28940538 | 0.83 | KDM4E (0.72) | KDM4EMAPTTDP1ALOX15ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030154501-A1 | Compound screening method | DEVGEN, N.V. (BE) | 2003-08-14 | — | — | US | claimed |
| EP-4301463-A1 | FULLERENE GABA DOPA AND METHODS | Pharmzandia Corporation (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117337183-A | Fullerene GABA dopa and methods | 赞迪亚制药公司 | 2024-01-02 | — | — | CN | disclosed |
| US-7674482-B2 | for producing acetylcholine and serotonin; improved cognitive function, induced and maintained sleep, reduced pain, inflammation, blood pressure, anxiety, asthma, duration of viral infection, insulin resistance, appetite, and treating depression | TARGETED MEDICAL PHARMA INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1996213-A2 | METHOD AND COMPOSITIONS FOR POTENTIATING PHARMACEUTICALS WITH AMINO ACID BASED MEDICAL FOODS | Shell, William E. (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007111958-A2 | METHOD AND COMPOSITIONS FOR POTENTIATING PHARMACEUTICALS WITH AMINO ACID BASED MEDICAL FOODS | SHELL WILLIAM E (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1689429-A1 | BIOMARKERS FOR THE EFFICACY OF SOMATOSTATIN ANALOGUE TREATMENT | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| EP-1682665-A2 | USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| US-20060159726-A1 | for producing acetylcholine and serotonin; improved cognitive function, induced and maintained sleep, reduced pain, inflammation, blood pressure, anxiety, asthma, duration of viral infection, insulin resistance, appetite, and treating depression | TARGETED MEDICAL PHARMA, INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2005053732-A1 | BIOMARKERS FOR THE EFFICACY OF SOMATOSTATIN ANALOGUE TREATMENT | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005045044-A2 | USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS | NOVARTIS AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| US-20030154501-A1 | Compound screening method | DEVGEN, N.V. (BE) | 2003-08-14 | — | — | US | disclosed |
| EP-0445218-A1 | NEURAL CELL TRANSPLANTATION | BAYLOR COLLEGE OF MEDICINE (US) | 1991-09-11 | — | — | EP | disclosed |
| WO-1990005781-A1 | NEURAL CELL TRANSPLANTATION | BAYLOR COLLEGE OF MEDICINE (US) | 1990-05-31 | — | — | WO | disclosed |